Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KRYS
BuyPremium GrowerFLAGKrystal Biotech, Inc. · Healthcare · United States · $10.4B · Avg Vol: $96M/d
Krystal Biotech has strong quality Q83 and momentum M76, but value at V16 is among the lowest scores in this run and far below the calibrated floor, so stage one fails. Insider selling is separately adverse.
COMPANY DESCRIPTION
Krystal Biotech, Inc. is a biotechnology company developing and commercializing gene therapies for patients with rare diseases, with an initial focus on serious dermatological conditions. Its proprietary "STAR-D" gene therapy platform provides a competitive moat by enabling repeat administration of gene therapies, distinguishing its approach in the rapidly evolving genetic medicine landscape. Krystal is a niche player with a lead product, Vyjuvek, now commercialized for Dystrophic Epidermolysis Bullosa (DEB).
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 50.7M | 290.5M | 389.1M | 177.0% | 440.5M | 512.6M | 654.5M | 29.7% |
| EPS | -5.49 | 0.40 | 3.12 | 7.08 | 320.7% | 7.99 | 8.14 | 9.73 | 17.2% |
| Shares | 25.8M | 28.2M | 28.8M | 29.2M | +13.3% | 29.6M | — | — | — |
| Debt | 8.9M | 8.1M | 7.3M | 9.3M | 1.5% | 8.9M | — | — | — |
| Equity | 522.2M | 778.6M | 946.4M | 1.2B | 32.7% | — | — | — | — |
| Op CF | -100.6M | -88.8M | 123.4M | 200.9M | 62.7% | 272.3M | — | — | — |
| Inv CF | -114.1M | 82.6M | -163.4M | -58.4M | — | — | — | — | — |
| Fin CF | 35.3M | 202.8M | 27.0M | 8.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KRYS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KRYS | Krystal Biotech, Inc.(you) | $10.4B | 74 | Buy |
| TECH | Bio-Techne Corporation | $11.3B | 76 | Buy |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 71 | Buy |
| BMRN | BioMarin Pharmaceutical Inc. | $12.5B | 63 | Hold |
| LGND | Ligand Pharmaceuticals Incorporated | $5.6B | 67 | Buy |
| CAI | Caris Life Sciences, Inc. | $7.2B | 60 | Hold |
| TGTX | TG Therapeutics, Inc. | $8.3B | 57 | Hold |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.0B | 83 | Strong Buy |
| HALO | Halozyme Therapeutics, Inc. | $12.0B | 95 | Strong Buy |
| TVTX | Travere Therapeutics, Inc. | $6.2B | 54 | Hold |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%